DekaBank Deutsche Girozentrale Increases Stake in Exelixis, Inc. (NASDAQ:EXEL)

DekaBank Deutsche Girozentrale boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 55.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 380,093 shares of the biotechnology company's stock after purchasing an additional 136,194 shares during the period. DekaBank Deutsche Girozentrale owned about 0.12% of Exelixis worth $9,065,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in EXEL. New York State Teachers Retirement System grew its holdings in shares of Exelixis by 2.6% in the 4th quarter. New York State Teachers Retirement System now owns 421,377 shares of the biotechnology company's stock valued at $10,109,000 after acquiring an additional 10,617 shares in the last quarter. Advisors Preferred LLC bought a new position in shares of Exelixis in the 4th quarter valued at about $3,384,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Exelixis by 340.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 35,975 shares of the biotechnology company's stock valued at $863,000 after acquiring an additional 27,809 shares in the last quarter. Braun Stacey Associates Inc. bought a new position in shares of Exelixis in the 4th quarter valued at about $10,414,000. Finally, State of Alaska Department of Revenue grew its holdings in shares of Exelixis by 236.3% in the 4th quarter. State of Alaska Department of Revenue now owns 127,287 shares of the biotechnology company's stock valued at $3,053,000 after acquiring an additional 89,436 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

Insider Activity

In other news, EVP Patrick J. Haley sold 47,020 shares of Exelixis stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the completion of the sale, the executive vice president now directly owns 384,866 shares in the company, valued at $8,255,375.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Exelixis news, EVP Patrick J. Haley sold 47,020 shares of the business's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the completion of the transaction, the executive vice president now directly owns 384,866 shares in the company, valued at $8,255,375.70. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David Edward Johnson acquired 190,000 shares of the stock in a transaction on Wednesday, February 21st. The shares were purchased at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the transaction, the director now owns 1,100,730 shares of the company's stock, valued at $22,785,111. The disclosure for this purchase can be found here. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

EXEL has been the subject of several analyst reports. Citigroup assumed coverage on Exelixis in a report on Friday, December 15th. They issued a "buy" rating and a $31.00 price objective for the company. TheStreet upgraded Exelixis from a "c+" rating to a "b-" rating in a report on Monday, March 18th. William Blair reiterated an "outperform" rating on shares of Exelixis in a report on Friday, January 26th. Stifel Nicolaus lifted their price target on Exelixis from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Friday, February 2nd. Finally, Royal Bank of Canada lifted their price target on Exelixis from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Wednesday, February 7th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Exelixis presently has a consensus rating of "Moderate Buy" and an average target price of $26.29.

Exelixis Trading Down 0.2 %

EXEL stock traded down $0.04 during mid-day trading on Wednesday, hitting $23.68. 1,477,259 shares of the company were exchanged, compared to its average volume of 2,306,260. The business has a 50 day simple moving average of $22.26 and a 200-day simple moving average of $22.10. The stock has a market capitalization of $7.18 billion, a PE ratio of 37.00, a price-to-earnings-growth ratio of 0.62 and a beta of 0.54. Exelixis, Inc. has a 1-year low of $18.08 and a 1-year high of $24.34.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.02. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. The company had revenue of $479.65 million during the quarter, compared to the consensus estimate of $481.23 million. Equities research analysts expect that Exelixis, Inc. will post 1.22 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.